Uveal melanoma metastatic to the liver: The role of quantitative volumetric contrast-enhanced MR imaging in the assessment of early tumor response after transarterialchemo

Rafael Duran, Julius Chapiro, Constantine Frangakis, Ming De Lin, Todd R. Schlachter, Rüdiger E. Schernthaner, Zhijun Wang, Lynn J. Savic, Vania Tacher, Ihab R. Kamel, Jean François Geschwind

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine whether volumetric changes of enhancement as seen on contrast-enhanced magnetic resonance (MR) imaging can help assess early tumor response and predict survival in patients with metastatic uveal melanoma after one session of transarterial chemoembolization (TACE). MATERIALS AND METHODS: Fifteen patients with 59 lesions who underwent MR imaging before and 3 to 4 weeks after the first TACE were retrospectively included. MR analysis evaluated signal intensities, World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL), modified RECIST (mRECIST), tumor volume [volumetric RECIST (vRECIST)], and volumetric tumor enhancement [quantitative EASL (qEASL)]. qEASL was expressed in cubic centimeters [qEASL (cm3)] and as a percentage of the tumor volume [qEASL (%)]. Paired t test with its exact permutation distribution was used to compare measurements before and after TACE. The Kaplan-Meier method with the log-rank test was used to calculate overall survival for responders and non-responders. RESULTS: In target lesions, mean qEASL (%) decreased from 63.9% to 42.6% (P =.016). No significant changes were observed using the other response criteria. In non-target lesions, mean WHO, RECIST, EASL, mRECIST, vRECIST, and qEASL (cm3) were significantly increased compared to baseline. qEASL (%) remained stable (P=.214).Median overall survival was 5.6 months. qEASL (cm3) was the only parameter that could predict survival based on target lesions (3.6 vs 40.5 months, P b.001) or overall (target and nontarget lesions) response (4.4 vs 40.9 months, P =.001). CONCLUSION: Volumetric tumor enhancement may be used as a surrogate biomarker for survival prediction in patients with uveal melanoma after the first TACE.

Original languageEnglish (US)
Pages (from-to)447-455
Number of pages9
JournalTranslational Oncology
Volume7
Issue number4
DOIs
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Uveal melanoma metastatic to the liver: The role of quantitative volumetric contrast-enhanced MR imaging in the assessment of early tumor response after transarterialchemo'. Together they form a unique fingerprint.

  • Cite this